Member Info for LiveLongnProsper

Great post from RAH on SpacetwiX …

https://x.com/RAH00084/status/1863156733880729790

Would just add a little more detail about how the (significant) side effects are treated. This from the Massachusetts General Hospital …

https://www.massgeneral.org/assets/mgh/pdf/cancer-center/breast-cancer/chemotherapy-regimen-keynote522-tc-first.pdf

KEYNOTE-522 is a ‘combo’ therapy - KEYTRUDA® (Pembrolizumab) plus Paclitaxel (Taxol), Carboplatin (Paraplatin), dose-dense Doxorubicin (Adriamycin), and dose-dense Cyclophosphamide (Cytoxan). So a relatively complex combination and treatment regimen.

A few ‘stand out’ points (for me anyway) …

Doxorubicin is part of the treatment regimen – could this be replaced by AVA6000?

If AVA6000 replaced ‘straight’ Dox, which, if any, of the the other chemo componets be required?

A large part of the document deals with the drugs used to treat side effects. If AVA6000 replaced Dox, then would the requirement to administer these side-effect treating drugs be reduced?

Just to highlight the scale of the opportunity ahead of us with both AVA6000 and AVA6103 …

Merck KEYTRUDA® (Pembrolizuma),

Daiichi Sankyo / AZN Enhertu (Trastuzumab Deruxtecan),

Gilead TRODELVY® (Sacituzumab Govitecan-hziy),

Lilly CanSEEK™ (pre|CISION® as licensed by Avacta),

Novartis – need FAP targeting for their RLT’s,

Many others, but the first 3 represent multi-$billions in revenue – how to protect this, BP folks?

GLA

Maybe a hint of things in the background, or a ‘nudge’ to interested parties (paraphrasing) ..?

Speaking about the ‘bystander effect’ @ ~14:20 – ‘that drug / radioligand’, then a few seconds later – ‘I mentioned radiotherapeutics’, then more about the bystander effect.

We know about Point (Lilly) and CanSEEK™(limited and non-exclusive licence), just wonder if anything else going on in this space? IMHO, Novartis (for one) need pre|CISION® here.

GLA

Https://x.com/avacta/status/1861717402041401836

GLA

Science great, impressive pipeline update, pre|CISION® platform looks like a real breakthrough, AVA6000 proving that point (and, potentially, suggesting more to dox than thought), AVA6103 could be a real ‘game changer’ (who knows, could supplant Enhertu?).

More trial data analysis next year (why next year?) – no doubt already being reviewed under NDA?

Science part of the Mark McKenna (Prometheus) playbook looking good …

https://www.youtube.com/watch?v=v5kstO1R2vA

(Must watch for all ‘engaged’ LTH’s and CC team).

Now for the commercial stuff.

CFO tricky, could be a short appointment?

Needs Pharma, acquisition, US capital markets, Nasdaq (IPO, RTO, etc.) experience – but tenure could be just a few months. So how to attract and reward the right person?

Probably a good idea to finish the FY with a CFO on board – even if we already have finance folks who can add numbers up.

In the meantime, looks like Darlene is now occupied elsewhere?

As for ‘busy’ Simon Bennett – time to get Dx ‘over the line’ (or just do something, anything ..).

GLA

Who might be interested in PDCs, Exatecan, targeted therapy, etc., etc.

Novartis a good start, seem to be ‘heavy’ on radioligand therapy – targeting FAP, PSMA, SSTR, others), particular focus on solid tumours …

https://www.novartis.com/research-development/novartis-pipeline?search_api_fulltext=&field_therapeutic_area%5B%5D=2771

Just a few (of quite a few more) below.

Sanofi … https://www.sanofi.com/en/our-science/our-pipeline

13 Oncology projects. Recent licensing agreement with Orano Med AlphaMedixTM (212Pb-DOTAMTATE), targeted alpha therapy based on a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb).

AZN … https://www.astrazeneca.com/r-d/next-generation-therapeutics/radioconjugates.html

“Radioconjugates are targeted medicines that combine a potent medical radioisotope, known as the payload, with a targeting molecule such as an antibody, peptide or small molecule via a chemical linker”. Key words – targeted, peptide, payload, linker.

AZN / Daiichi Sankyo – Enhertu …

https://www.astrazeneca.com/media-centre/press-releases/2024/Enhertu-demonstrated-median-progression-free-survival-thirteen-months.html

Enhertu is trastuzumab deruxtecan. Trastuzumab targets HER2 proteins (expressed by breast cancer), deruxtecan is the payload – a topoisomerase I inhibitor that interferes with cancer cell DNA, thus preventing replication and leading to cell death.

Exatecan (from which deruxtecan is derived) is more powerful, but needs to be ‘precisely’ targeted (i.e. AVA6103).

A few others who are active in ADCs and researching PDCs …

Merck, Pizer, Amgen.

Then we have Lilly who acquired Point (CanSEEK™) last year.

Consider which BP’s are working on what, who needs to partner / acquire due to programme problems / pipeline gaps, or just running out of patent ‘cover’ soon – more research. Yep, ‘could be any of them’.

GLA

@VT, a few thoughts.

Page 6 of the TD update of 18 November …

“Legacy collaborations continue to progress and require little management time”.

“Active partnerships include POINT Biopharma (Eli Lilly) for the development of FAP-activated radiopharmaceuticals (the most advanced asset 177Lu-PNT2004 is in Phase I); a multi-target Affimer protein development agreement with LG Chem Life Sciences which included an extension to incorporate Affimer XT systemic half-life extension technology and exercise of a renewal option, and the AffyXell Therapeutics joint venture with Daewoong Pharmaceutical in which Avacta currently holds a 25% equity stake.”

Rather dismissive? Just low key? Something happening they don’t want to talk about?

Or just that management absolutely focused on other stuff (e.g. Dx, Nasdaq, AVA6000 P1b, AVA6000 ‘fast track’, AVA6103 IND, etc.)?

GLA

@BV, haha, absolute classic series. I guess the retort is 'great'. Great things to come from Avacta that is.

GLA

Https://x.com/coughlin582

@Hurst10, brilliant!

GLA

Yep, ‘shop front’ (R&D day, website, etc.) sorted and wares on display.

Summary of performance to date demonstrates outstanding capability.

Innovation ongoing, more products to come, initial results ‘super’ good.

(I learnt the word ‘super’ from watching a couple of recent ‘AI tech guru’ videos – we do have Tempus AI engaged after all).

Review of product detail likely by invitation only (and under NDA).

More (hopefully, exceptional) performance results to come.

A couple of notes released – TD, now Peel. As noted by @Hurst10, likely warm up for ‘heavyweights’ and Nasdaq action.

Dx news next?

GLA

Thanks @gmcc. Good to see Coris getting on with growing their business.

Coris and Launch looking quite distinct in terms of their websites, branding, etc. No particular link evident between the companies, except the ‘about’ pages with passing references to being part of the Avacta Group.

Though, Launch are selling Coris products …

https://www.launchdiagnostics.com/?s=coris

Worth noting (probably already discussed), that TD valuation @ 111p / share (fully diluted) based on …

“excluding the convertible bond, CB, which we assume will be settled in shares”.

But, additionally notes that …

“we also do not factor in potential proceeds from any Diagnostics sale.”

Selling Dx clearly key to sorting out the SP. (Yes, I know the ‘Probability’ of success placed on AVA6000 (30%), AVA6103 (15%) and other aspects of the valuation model are extremely conservative, to say the least).

So back to Coris and Launch – sell separately or together (as Avacta Dx), do Coris take any Affimer rights, same question if Dx sold as a whole? What deal construct offers best value to Avacta shareholders?

SB must be very ‘busy’ reviewing the incoming bids?

GLA

Https://x.com/Jenkoool/status/1857881869812986051

@Jenkool from SpacetwiX suggests CC mentioned ‘Gilead’ at the R&D spotlight.

Not knocking the research, definetly worth a post, but I suspect the reference is to a colleague though …

Co-authors of the AVA6000 study (presentation 646P) at ESMO 2024:

15. Gilad Gordon (Berwyn, USA). Clinical Development Specialist in Oncology, especially novel targeted therapies in solid tumors.

(Of course if it was Gilead that CC mentioned by ‘slip of tongue’ that would be nice, given that Trodelvy (Sacituzumab Govitecan) from Gilead, targets Trop-2 and delivers the topoisomerase I inhibitor SN-38, used for metastatic TNBC and others – and Exatecan has a much higher inhibitory effect on topoisomerase I activity than SN-38.)

GLA

The science is truly brilliant, and we’ve had …

The play R&D (live event),

The first edition of the book,

The film of the book,

The second edition of the book,

The art work (new web site),

And now, the mood music – which was remarkably relaxing.

What will really ‘chill me out’ though, is a ‘top notch’ commercial deal.

GLA

Think this thread from @yuyus and developed by BV deserves a little more attention.

Reported in the Pharma press today …

https://www.pharmaceutical-business-review.com/news/astrazeneca-daiichi-bla-lung/

As discussed at the R&D day, Deruxtecan is a derivative of Exatecan, modified for delivery via ADC’s. AZN / DS clearly working ‘hand-in-glove’ with the FDA. Our turn soon (with the real ‘thing’) eh?

My post yesterday re Alteogen was taken down – possibly hi-jacked by ‘green box’ creatures? With apologies for the repetition, as it relates to Enhertu (trastuzumab deruxtecan), also by Daiichi Sankyo and AstraZeneca …

Alteogen (South Korea) have done a LD with Daiichi Sankyo to do some work on Enhertu …

https://www.pharmaceutical-business-review.com/news/alteogen-daiichi-sankyo-adc/

SP rises from 387,500 KRW on Fri 8/11 to close at 445,500 KRW today (12/11/24).

2023 revenue ~USD$50m, mcap currently ~USD$13bn. Decent multiple?

Alteogen do ‘biosimilars’ and ‘biobetters’. Much more interestingly, they also do NexMab™ ADC Technology …

http://www.alteogen.com/en/technology_2/

“The highly cytotoxic payloads are connected to antibody via chemical linkers. The chemistry of the linker determines the characteristic of ADC. Using NexMab™ ADC technology, Alteogen is developing multiple anti-cancer drugs as the second-generation ADCs.”

No doubt AZN / DC are well aware of AVA6103, question is whether ‘busy’ Simon Bennett is engaged with said parties or others.

GLA

Ps – posts from @NFTs present a strong but realistic message to Avacta – time to demonstrate commercial acumen.

Cont'd ..

‘Getting data from phase 2 is where the value inflection happens’.

‘Did evaluate a partnership process ahead of that data’. Various scenarios considered dependent on data outcome.

Data good, pivot ‘play book’ to operating as an independent company.

‘All the big funds seeing the opportunity of a novel target breaking through in a big drug class’.

‘Best way to create value for your shareholders is create a competitive process’.

Etc.

Brilliant video.

Should be compulsory watching for CC, (busy) SB, new CFO, et al.

GLA

@gmcc, yes, brilliant.

Thanks to Tom_The_Bomb_ (https://x.com/Tom_The_Bomb__) from SpacetwiX .

Mark McKenna re Prometheus (paraphrasing).

‘We had a acquired a diagnostic business to help support the precision medicine aspiration’.

‘Investors really struggle with mixed business model companies’.

‘Decoupling Diagnostics from Therapeutics would create value for both businesses’.

‘Small European investor comes in to give 12 months more runway, ahead of blue chip investors’.

IPO in 2021, ~$700m to ~$5bn in

Exhibiting at the Medica trade fair in Dusseldorf next week …

https://www.medica-tradefair.com/vis/v1/en/exhprofiles/RYTW5rCtQxKUyE89034l1g

Another trip out for DW (get them in before DX sold). “Looking forward to a great week of networking, meeting colleagues and partners, and catching up on developments in the global in vitro diagnostics markets.”

How about doing some ‘deals’ David, you are still (supposed to be) a CCO?

https://www.linkedin.com/in/davidswilson/

GLA

Https://www.londonstockexchange.com/stock/AVCT/avacta-group-plc/trade-recap

2024-11-08T16:35:29Z GBp 4900 361633 17,720,017 Off-book XOFF

Not edited (or yet corrected). Not £200 ex-Chi-n-ah I know, but guess I would, reluctantly, probably take that price.

GLA

More to come’…

New CFO.

DX sale.

Phase 1b / Expansion cohorts – what is the dosing regimen, what are the indications, any input from SOFIE [18F]FAPI-74 PET scanning study, has there been any feed in from Tempus (say) ‘smart trial matching’ yet … etc.?

AVA6103 progress, interest in from (as yet unnamed) ‘parties’ …?

How to get listed on Nasdaq?

Nearly forgot – ‘the film of the book’.

GLA

@GS, 'all this info presented'?

Presented to a few, but not (yet) most.

Looking forward to the video - soon, please Avacta.

GLA

Are we reading too much into the use of words, or does ‘franchise’ mean …

Opening up the availability of the platform to any (suitable) pharma who wants (to pay for) it?

Licensing by (say) indication, warhead, geography, etc.?

And do we have someone already ‘signed up’?

Do we become a platform provider / IP holder for multiple BP programmes?

If, as we expect, pre|CISION® is a game changer then this approach does seem a good way to reach patients as quickly as possible. Let’s see.

GLA